Mabion S.A.

Warsaw Stock Exchange MAB.WA

Mabion S.A. Price to Earnings Ratio (P/E) on January 14, 2025: 3.61

Mabion S.A. Price to Earnings Ratio (P/E) is 3.61 on January 14, 2025, a -51.62% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Mabion S.A. 52-week high Price to Earnings Ratio (P/E) is 7.73 on August 21, 2024, which is 114.04% above the current Price to Earnings Ratio (P/E).
Mabion S.A. 52-week low Price to Earnings Ratio (P/E) is 3.18 on December 23, 2024, which is -11.87% below the current Price to Earnings Ratio (P/E).
Mabion S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is 6.23.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	241
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Key trends

Past 5 years